scholarly journals Tumour response 3 months after neoadjuvant single-fraction radiotherapy for low-risk breast cancer

2020 ◽  
Vol 27 (3) ◽  
Author(s):  
D. Tiberi ◽  
P. Vavassis ◽  
D. Nguyen ◽  
M. C. Guilbert ◽  
A. Simon-Cloutier ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Stage ◽  
Tumour Response ◽  
Breast Conserving Surgery ◽  
Early Stage Breast Cancer ◽  
Primary Breast Tumor ◽  
Luminal A ◽  
Single Fraction ◽  
Novel Approach ◽  
Microscopic Evaluation

Introduction Standard treatment for early-stage invasive breast cancer consists of breast-conserving surgery (BCS) and several weeks of adjuvant radiotherapy (RT). Neoadjuvant single-fraction RT is a novel approach for early-stage breast cancer. We sought to investigate the effect of delaying surgery after neoadjuvant RT with respect to the rates pathological response (PR).   Materials and Methods Women aged 65 years or older with a new diagnosis of stage I, luminal A, breast cancer were eligible for inclusion. A single dose of 20 Gy to the primary breast tumor was given followed by BCS 3 months later. The primary endpoint was the rate of PR as assessed by microscopic evaluation using the Miller-Payne system.   Results 10 patients were successfully treated to date. The median age of the patients was 72 years (65-84). 8 patients had a pathological tumor response (PR) to neoadjuvant RT with a median residual cellularity of 3%. No immediate RT complications were noted other than mild dermatitis. Conclusions This study demonstrates a method for delivering single fraction RT that can lead to high levels of PR in most patients. Continued accrual of this study and subsequent trials are needed to determine the feasibility, safety and role of this novel technique in the management of early-stage breast cancer.  

scholarly journals Associated Factors and Survival Outcomes for Breast Conserving Surgery versus Mastectomy among New Zealand Women with Early-Stage Breast Cancer

2021 ◽  
Vol 18 (5) ◽  
pp. 2738
Author(s):  
Mohammad Shoaib Abrahimi ◽  
Mark Elwood ◽  
Ross Lawrenson ◽  
Ian Campbell ◽  
Sandar Tin Tin
Keyword(s):  
Breast Cancer ◽  
Regression Analysis ◽  
New Zealand ◽  
Early Stage ◽  
Breast Conserving Surgery ◽  
Early Stage Breast Cancer ◽  
Clinical Factors ◽  
Breast Cancer Specific Mortality ◽  
Specific Mortality ◽  
Cancer Specific Mortality

This study aimed to investigate type of loco-regional treatment received, associated treatment factors and mortality outcomes in New Zealand women with early-stage breast cancer who were eligible for breast conserving surgery (BCS). This is a retrospective analysis of prospectively collected data from the Auckland and Waikato Breast Cancer Registers and involves 6972 women who were diagnosed with early-stage primary breast cancer (I-IIIa) between 1 January 2000 and 31 July 2015, were eligible for BCS and had received one of four loco-regional treatments: breast conserving surgery (BCS), BCS followed by radiotherapy (BCS + RT), mastectomy (MTX) or MTX followed by radiotherapy (MTX + RT), as their primary cancer treatment. About 66.1% of women received BCS + RT, 8.4% received BCS only, 21.6% received MTX alone and 3.9% received MTX + RT. Logistic regression analysis was used to identify demographic and clinical factors associated with the receipt of the BCS + RT (standard treatment). Differences in the uptake of BCS + RT were present across patient demographic and clinical factors. BCS + RT was less likely amongst patients who were older (75+ years old), were of Asian ethnicity, resided in impoverished areas or areas within the Auckland region and were treated in a public healthcare facility. Additionally, BCS + RT was less likely among patients diagnosed symptomatically, diagnosed during 2000–2004, had an unknown tumour grade, negative/unknown oestrogen and progesterone receptor status or tumour sizes ≥ 20 mm, ≤50 mm and had nodal involvement. Competing risk regression analysis was undertaken to estimate the breast cancer-specific mortality associated with each of the four loco-regional treatments received. Over a median follow-up of 8.8 years, women who received MTX alone had a higher risk of breast cancer-specific mortality (adjusted hazard ratio: 1.38, 95% confidence interval (CI): 1.05–1.82) compared to women who received BCS + RT. MTX + RT and BCS alone did not have any statistically different risk of mortality when compared to BCS + RT. Further inquiry is needed as to any advantages BCS + RT may have over MTX alternatives.

Emerging radiation techniques for early-stage breast cancer after breast-conserving surgery

2011 ◽  
Vol 7 (7) ◽  
pp. 915-925 ◽  
Author(s):  
Janice A Lyons ◽  
Charles Woods ◽  
Nicholas Galanopoulos ◽  
Paula Silverman
Keyword(s):  
Breast Cancer ◽  
Early Stage ◽  
Breast Conserving Surgery ◽  
Early Stage Breast Cancer

scholarly journals Accelerated Partial Breast Irradiation as an Alternative to Whole-Breast Irradiation in Breast-Conserving Therapy for Early-Stage Breast Cancer

2005 ◽  
Vol 1 (1) ◽  
pp. 59-71
Author(s):  
Timothy M Pawlik ◽  
Henry M Kuerer
Keyword(s):  
Breast Cancer ◽  
Early Stage ◽  
Local Therapy ◽  
Breast Conserving Surgery ◽  
Breast Conserving Therapy ◽  
Early Stage Breast Cancer ◽  
Accelerated Partial Breast Irradiation ◽  
Partial Breast Irradiation ◽  
Whole Breast Irradiation ◽  
Breast Irradiation

Breast-conserving therapy has been established as a standard treatment for women with early-stage breast cancer. Whole-breast irradiation has traditionally been utilized to consolidate local therapy following conservative surgery. Recently, the need for whole-breast irradiation after breast-conserving surgery has become controversial, with some investigators advocating accelerated partial breast irradiation as an alternative. Accelerated partial breast irradiation is delivered over a shorter period and only to a portion of the breast. This review will examine the emerging role of accelerated partial breast irradiation in the treatment of early-stage breast cancer and review the biologic rationale for, techniques of, and limitations of partial breast irradiation following breast-conserving surgery.

Sign in / Sign up

Export Citation Format

Share Document